Targeting a viral enzyme to fight herpes simplex virus infections.
Official title: Targeting the UL37 deamidase to impede HSV-1 infection.
Funded at University of Southern California · NIH-11088712 · Data updated 2026-11-12
This study is looking for new ways to help people with weakened immune systems, like those with AIDS, fight the herpes virus by targeting a specific part of the virus, and it aims to find effective treatments that work even when the virus becomes resistant to current medications.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | May 14, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $201,275 |
| NIH project number | 5R21AI180537-02 |
| Project ID | NIH-11088712 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with weakened immune systems, such as those living with HIV/AIDS or other conditions that compromise immune function.
✕Less likely to help
Patients with healthy immune systems and no history of herpes simplex virus infections may not benefit from this research.
What this research studies
This research focuses on developing new antiviral treatments for herpes simplex virus type 1 (HSV-1) by targeting a specific viral enzyme called UL37 deamidase. The study aims to restore the body's immune response against the virus, particularly in individuals with weakened immune systems, such as those with AIDS. Researchers will identify and test compounds that inhibit this enzyme, using advanced techniques like mass spectrometry and structural analysis to understand how these inhibitors work. The goal is to create effective treatments that can overcome the growing problem of drug resistance in herpes viruses.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral therapies that effectively combat HSV-1 infections, especially in immunocompromised patients.
How similar studies have gone: Other research has shown promise in targeting viral enzymes to enhance immune responses, indicating that this approach could be effective.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Feng, Pinghui — University of Southern California
- Study coordinator: Feng, Pinghui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.